Pharmaceutical - Asia-Pacific, Oncology

Filter

Current filters:

Asia-PacificOncology

Popular Filters

1 to 25 of 124 results

Bristol-Myers and Ono Pharma enter Asia oncology accord

Bristol-Myers and Ono Pharma enter Asia oncology accord

24-07-2014

US pharma major Bristol-Myers Squibb and Japan’s Ono Pharmaceutical have signed a strategic collaboration…

Asia-PacificBristol-Myers SquibbJapanLicensinglirilumabMelanomaOncologyOno PharmaceuticalOpdivoPharmaceuticalurelumabYervoy

SillaJen changes its name to mark Jennerex acquisition

20-06-2014

South Korean privately held pharma company SillaJen has changed its name to SillaJen Biotherapeutics…

Asia-PacificJennerexManagementMergers & AcquisitionsOncologyPexa-VecPharmaceuticalSillaJen

Greater brand-drug adoption fuels Asia-Pacific breast cancer market

09-05-2014

Due to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics…

afatinibAsia-PacificBoehringer IngelheimEisaiHalavenKadcylaMarkets & MarketingneratinibOncologypalbociclibPerjetaPfizerPharmaceuticalResearchRoche

Astellas’ Xtandi cleared in Japan for prostate cancer treatment

24-03-2014

Japanese drug major Astellas Pharma has obtained the marketing approval in Japan of its oral androgen…

Asia-PacificAstellas PharmaJapanMedivationOncologyPharmaceuticalRegulationXtandi

Japanese approval for Forxiga and Lonsurf

24-03-2014

Anglo-Swedish drug major AstraZeneca says that Japanese Ministry of Health, Labor and Welfare approved…

Asia-PacificAstraZenecaDiabetesForxigaJapanLonsurfOncologyOno PharmaceuticalOtsukaPharmaceuticalRegulationTaiho Pharmaceutical

Latest Australian PBS Listings include medicines for children

Latest Australian PBS Listings include medicines for children

19-03-2014

Ten new medicines to treat a range of illnesses from rare forms of cancer to skin conditions will be…

Anti-Arthritics/RheumaticsAsia-PacificAustraliaDermatologicalsDiabetesGastro-intestinalsHealthcareOncologyPharmaceuticalPricing

Asia-Pacific NSCLC market to reach $2.9 billion by 2019

Asia-Pacific NSCLC market to reach $2.9 billion by 2019

18-03-2014

The non-small cell lung cancer (NSCLC) therapeutics market value in the Asia-Pacific (APAC) region -…

Asia-PacificAustraliaChinaIndiaJapanMarkets & MarketingOncologyPharmaceutical

AstraZeneca to establish cancer research program with Korea’s HIDI

AstraZeneca to establish cancer research program with Korea’s HIDI

07-03-2014

Anglo-Swedish pharma major AstraZeneca has signed a memorandum of understanding (MoU) with the South…

Asia-PacificAstraZenecaOncologyPharmaceuticalResearch

Biostar Pharma partners with Shaanxi University to co-develop liver cancer drug

06-03-2014

China-based pharma and health supplements firm Biostar Pharmaceuticals (Nasdaq: BSPM) has signed a letter…

Asia-PacificBiostar PharmaChinaOncologyPharmaceutical

Australian patients benefit from PBS changes; cancer research

27-02-2014

New medicines for glaucoma, diabetes and advanced soft tissue sarcoma have been approved for listing…

Asia-PacificAustraliaDiabetesFinancialHealthcareKombiglyzeOncologyPharmaceuticalResearchTrajentaVotrient

Roche sues Biocon and Mylan over Herceptin biosimilar; US puts pressure on India over IP

Roche sues Biocon and Mylan over Herceptin biosimilar; US puts pressure on India over IP

10-02-2014

Swiss pharma major Roche’s Indian subsidiary has sued Bangalore-based Biocon and US generics firm Mylan…

Asia-PacificBioconBiosimilarsCanmabHerceptinHertrazIndiaLegalMylan LaboratoriesOncologyPatentsPharmaceuticalRegulationRoche

Kinex and PharmaEssentia expand drug development partnership

06-02-2014

Privately-held USA-based Kinex Pharmaceuticals and Taiwan’s PharmaEssentia say they have signed a new…

Asia-PacificKinex PharmaceuticalsLicensingOncologyOratecanOraxolPharmaceuticalPharmaEssentia

AbbVie to spend $320 million to establish Singapore manufacturing presence

AbbVie to spend $320 million to establish Singapore manufacturing presence

06-02-2014

US drugmaker AbbVie says it plans to invest $320 million to establish operations in Singapore for small…

AbbVieAsia-PacificImmunologicalsOncologyPharmaceuticalProduction

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

31-01-2014

Belgium-based VIB, a non-profit research institute in life sciences, and the Center for Drug Design and…

Asia-PacificAstraZenecaIndiaInflammatory diseasesOncologyPharmaceuticalResearchTropical diseases

Ariad Pharma plans commercialization of Iclusig in Australia

Ariad Pharma plans commercialization of Iclusig in Australia

28-01-2014

US specialty pharma firm Ariad Pharmaceuticals has signed an agreement with Specialised Therapeutics…

Ariad PharmaceuticalsAsia-PacificAustraliaIclusigLicensingOncologyPharmaceuticalSpecialised Therapeutics Australia

Advaxis out-licenses ADXS-HPV to Biocon for emerging markets

Advaxis out-licenses ADXS-HPV to Biocon for emerging markets

23-01-2014

Indian biotech firm Biocon has entered into an exclusive licensing agreement for US cancer drug developer…

AdvaxisADXS-HPVAsia-PacificBioconIndiaLicensingOncologyPharmaceuticalWomen's Health

Norgine and Kissei’s Savene approved in Japan

21-01-2014

Independent Dutch firm Norgine and its Japanese partner Kissei Pharmaceutical received approval from…

Asia-PacificKissei PharmaceuticalNorgineOncologyPharmaceuticalRegulationSavene

Galena Biopharma links with and Dr Reddy's for NeuVax in India

14-01-2014

USA-based Galena Biopharma and India’s second-largest drugmaker Dr Reddy's Laboratories have entered…

Asia-PacificDr Reddy's LaboratoriesGalena BioPharmaIndiaLicensingNeuVaxOncologyPharmaceutical

Lung cancer treatment takes another forward step in New Zealand

Lung cancer treatment takes another forward step in New Zealand

09-01-2014

Improvements in lung cancer treatment are set to continue with a decision for New Zealand’s Pharmaceutical…

Asia-PacificAstraZenecaFinancialHealthcareIressaOncologyPharmaceuticalRocheTarceva

Ono Pharma files for approval of nivolumab for melanoma in Japan

30-12-2013

Japanese drugmaker Ono Pharmaceutical has filed an application to obtain a manufacturing and marketing…

Asia-PacificBristol-Myers SquibbnivolumabOncologyOno PharmaceuticalPharmaceuticalRegulation

Helsinn and Mundipharma collaborate on netupitant-palonosetron for China

Helsinn and Mundipharma collaborate on netupitant-palonosetron for China

23-12-2013

Privately-held Swiss drugmakers Helsinn and Mundipharma have signed a new, exclusive license and distribution…

Asia-PacificChinaHelsinnLicensingMundipharmanetupitantOncologypalonosetronPharmaceutical

Fast growth forecast for China’s colorectal cancer market

Fast growth forecast for China’s colorectal cancer market

13-12-2013

From 2012 to 2017, the colorectal cancer therapy market in China will grow at an annual rate of 9%, from…

AmgenAsia-PacificBayerIndiaMarkets & MarketingOncologyPharmaceuticalSanofiStivargaVectibixZaltrap

New Zealand funding plans for Tarceva and Revolade

New Zealand funding plans for Tarceva and Revolade

09-12-2013

Following a consultation, New Zealand’s Pharmaceutical Management Agency PHARMAC said this morning…

Asia-PacificGlaxoSmithKlineHematologyNew ZealandOncologyPharmaceuticalPricingRegulationRevoladeRocheTarceva

Different Rxing patterns for premium-priced therapies in China and South Korea

26-11-2013

In China, a combination of government restrictions on reimbursement and regional variations in formulary…

Asia-PacificMarkets & MarketingOncologyPharmaceuticalPricing

1 to 25 of 124 results

Back to top